دورية أكاديمية
Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors.
| العنوان: | Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors. |
|---|---|
| المؤلفون: | Lammers EMJ; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nijdam A; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zijlstra JM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Cancer Centre Amsterdam, Amsterdam, The Netherlands., Janus CPM; Department of Radiation Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands., de Weijer RJ; Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands., Appelman Y; Department of Cardiology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands., Manintveld OC; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Teske AJ; Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands., van Leeuwen FE; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Aleman BMP; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.aleman@nki.nl. |
| المصدر: | Journal of cancer survivorship : research and practice [J Cancer Surviv] 2024 Apr 23. Date of Electronic Publication: 2024 Apr 23. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 101307557 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-2267 (Electronic) Linking ISSN: 19322259 NLM ISO Abbreviation: J Cancer Surviv Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, N.Y. : Springer Science + Business Media, c2007- |
| مستخلص: | Purpose: Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular disease (CVD) due to former lymphoma treatment. In 2013, cardiovascular screening for 5-year HL survivors according to national guidelines was implemented in Dutch survivorship clinics. We aim to assess the following: (1) adherence to screening guidelines and (2) the yield of (risk factors for) CVD in the screening program. Methods: The study population consisted of 5-year HL survivors who received survivorship care at three University Medical Centers from 2013 to 2016 through 2021. Patient characteristics, cardiovascular screening procedures, and outcomes were collected from the medical records. Results: In 186 survivors eligible for cardiovascular screening (mean age 47.8 years, 60.8% female), the following diagnostics were performed: complete blood tests (81.0%, median frequency: yearly instead of advised 5-yearly evaluation), electrocardiogram (93.0%), echocardiography (94.6%). Fifty-five percent of survivors had at least one modifiable cardiovascular risk factor (i.e., current smoking, overweight, new/insufficiently controlled hypertension, dyslipidemia, or diabetes). Screening detected ≥ 1 CVD in 31.1% of survivors. Among survivors with available echocardiography report (n = 106), screening detected new aortic and/or mitral valve dysfunction(s) in 51.0% (with grades 3-4 in 4.9%) and impaired left ventricular ejection fraction in 10.3%. Conclusions: Adherence to the screening guidelines in the Dutch HL survivorship care program was reasonable to good and a substantial number of actionable (risk factors for) CVD were diagnosed. Implications for Cancer Survivors: Our findings inform HL survivors at high risk of late cardiotoxicity about cardiovascular screening findings and demonstrate appropriate therapeutic actions after diagnosis of (risk factors for) CVD. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450–9. https://doi.org/10.1038/nrclinonc.2012.91 . (PMID: 10.1038/nrclinonc.2012.9122688578) Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19–29. https://doi.org/10.1093/annonc/mdy080 . Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209–15. https://doi.org/10.1053/j.seminhematol.2016.05.008 . (PMID: 10.1053/j.seminhematol.2016.05.00827496313) de Vries S, Schaapveld M, van Nimwegen FA, Jozwiak K, Lugtenburg PJ, Daniels LA, et al. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. Br J Cancer. 2018;118(6):887–95. https://doi.org/10.1038/bjc.2017.476 . (PMID: 10.1038/bjc.2017.476293816855886118) Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van ’t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86. https://doi.org/10.1182/blood-2006-07-034405 . (PMID: 10.1182/blood-2006-07-03440517119114) van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17. https://doi.org/10.1001/jamainternmed.2015.1180 . (PMID: 10.1001/jamainternmed.2015.118025915855) Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99. https://doi.org/10.1093/eurheartj/ehab674 . (PMID: 10.1093/eurheartj/ehab67434904661) Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486–93. https://doi.org/10.1080/10428190802140873 . (PMID: 10.1080/1042819080214087318608873) Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864–71. https://doi.org/10.1001/jamaoncol.2018.6634 . (PMID: 10.1001/jamaoncol.2018.6634307031926490232) Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007;25(24):3635–43. https://doi.org/10.1200/JCO.2006.09.7451 . (PMID: 10.1200/JCO.2006.09.745117704413) van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42(18):3191–8. https://doi.org/10.1016/j.ejca.2006.08.005 . (PMID: 10.1016/j.ejca.2006.08.00516987655) McCabe MS, Faithfull S, Makin W, Wengstrom Y. Survivorship programs and care planning. Cancer. 2013;119(Suppl 11):2179–86. https://doi.org/10.1002/cncr.28068 . (PMID: 10.1002/cncr.2806823695930) Barbui T, Bjorkholm M, Gratwohl A. Cancer survivorship programs: time for concerted action. Haematologica. 2014;99(8):1273–6. https://doi.org/10.3324/haematol.2014.104059 . (PMID: 10.3324/haematol.2014.104059250827844116824) Nijdam A, Dekker N, Aleman BMP, van ‘t Veer MB, Daniels LA, van der Maazen RW, et al. Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma. Br J Haematol. 2019;186(4):103–8. https://doi.org/10.1111/bjh.15936 . (PMID: 10.1111/bjh.15936) Dutch society for Radiation Therapy and Oncology (NVRO). Cardiovascular adverse effects after Hodgkin lymphoma. 2016. https://richtlijnendatabase.nl/richtlijn/cardiovasculaire_schade_na_hodgkinlymfoom/cardiovasculaire_hodgkinlymfoom_-_startpagina.html#:~:text=Zo%20kan%20bestraling%20en%20chemotherapie,ontwikkelen%20van%20hart%2D%20en%20vaatziekten . Accessed 3 July 2023. Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study. J Am Coll Cardiol. 2015;65(23):2511–22. https://doi.org/10.1016/j.jacc.2015.04.013 . (PMID: 10.1016/j.jacc.2015.04.013260659904539123) Palmer C, Mazur W, Truong V, Nagueh S, Fowler J, Shelton K, et al. Prevalence of diastolic dysfunction in adult survivors of childhood cancer. J Am Coll Cardiol CardioOnc. 2023;5(3):377–88. https://doi.org/10.1016/j.jaccao.2022.12.010 . (PMID: 10.1016/j.jaccao.2022.12.010) American College of Cardiology. Left ventricular ejection fraction LVEF assessment (outpatient setting). https://www.acc.org/tools-and-practice-support/clinical-toolkits/~/media/1E4D8F9B69D14F55821BFE642FBFA221.ashx . Accessed 3 July 2023. Chow EJ, Chen Y, Armstrong GT, Baldwin LM, Cai CR, Gibson TM, et al. Underdiagnosis and undertreatment of modifiable cardiovascular risk factors among survivors of childhood cancer. J Am Heart Assoc. 2022;11(12):e024735. https://doi.org/10.1161/JAHA.121.024735 . (PMID: 10.1161/JAHA.121.024735356743439238650) Tijn-A-Ton JJS, Konings KTS. Dutch college of general practioners (NHG) guideline cardiovascular risk management version 4.0. https://richtlijnen.nhg.org/standaarden/cardiovasculair-risicomanagement . Accessed 3 July 2023. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract. 2007;24(6):555–61. https://doi.org/10.1093/fampra/cmm052 . (PMID: 10.1093/fampra/cmm05217962235) Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9. https://doi.org/10.1016/s0735-1097(03)00759-9 . (PMID: 10.1016/s0735-1097(03)00759-912932613) Wethal T, Lund MB, Edvardsen T, Fossa SD, Pripp AH, Holte H, et al. Valvular dysfunction and left ventricular changes in Hodgkin’s lymphoma survivors. A longitudinal study Br J Cancer. 2009;101(4):575–81. https://doi.org/10.1038/sj.bjc.6605191 . (PMID: 10.1038/sj.bjc.660519119623176) Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72–227. https://doi.org/10.1161/CIR.0000000000000923 . (PMID: 10.1161/CIR.000000000000092333332150) Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–80. https://doi.org/10.1016/j.jacc.2021.12.011 . (PMID: 10.1016/j.jacc.2021.12.01135379504) Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977–82. https://doi.org/10.1161/01.CIR.0000085166.44904.79 . (PMID: 10.1161/01.CIR.0000085166.44904.7912912813) Mulrooney DA, Armstrong GT, Huang S, Ness KK, Ehrhardt MJ, Joshi VM, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med. 2016;164(2):93–101. https://doi.org/10.7326/M15-0424 . (PMID: 10.7326/M15-0424267470864809016) Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022. https://doi.org/10.1093/ehjci/jeac106 . (PMID: 10.1093/ehjci/jeac10636017575) Wu S, Chai A, Arimie S, Mehra A, Clavijo L, Matthews RV, et al. Incidence and treatment of severe primary mitral regurgitation in contemporary clinical practice. Cardiovasc Revasc Med. 2018;19(8):960–3. https://doi.org/10.1016/j.carrev.2018.07.021 . (PMID: 10.1016/j.carrev.2018.07.02130060923) Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, et al. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study. JACC Cardiovasc Imaging. 2016;9(3):230–9. https://doi.org/10.1016/j.jcmg.2015.06.028 . (PMID: 10.1016/j.jcmg.2015.06.02826897666) Mulrooney DA, Hyun G, Ness KK, Ehrhardt MJ, Yasui Y, Duprez D, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ. 2020;368:l6794. https://doi.org/10.1136/bmj.l6794 . (PMID: 10.1136/bmj.l6794319416577190022) Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol. 2021;3(3):343–59. https://doi.org/10.1016/j.jaccao.2021.06.007 . (PMID: 10.1016/j.jaccao.2021.06.007346047968463722) |
| معلومات مُعتمدة: | 10330022010009 Netherlands ZONMW_ ZonMw; 10330022010009 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Keywords: Cardiovascular disease; Cardiovascular risk factors; Hodgkin lymphoma; Screening; Survivorship care |
| تواريخ الأحداث: | Date Created: 20240422 Latest Revision: 20240422 |
| رمز التحديث: | 20240424 |
| DOI: | 10.1007/s11764-024-01561-y |
| PMID: | 38649650 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1932-2267 |
|---|---|
| DOI: | 10.1007/s11764-024-01561-y |